Fig. 1From: Safety and efficacy of first-in-man intrathecal injection of human astrocytes (AstroRx®) in ALS patients: phase I/IIa clinical trial resultsPhase 1/2a study design and study flowchart. A Visit 0 (V0) - screening visit, visit 1 (V1) till visit 4 (V4) presents about 3 months run-in period (pre-treatment), AstroRx injection was performed on V4. V4 till visit V10 is the 6 months follow up time under ASTRO-001 study and additional 6 months follow up was performed under study ASTRO-002 on V10-V12 and by phone call. B Study flow chart of patient allocation, treatment doses of ASTRO-001 and ASTRO-002. V Visit, mo Month, BCV Blood Count Visit, EOS End of StudyBack to article page